Dr. Dignam's primary research involves the design, conduct, and analysis of cancer clinical trials, including early development (phase I), pilot efficacy and safety (phase II), and definitive evaluation (phase III) trials. He is the Executive Director of the Statistics and Data Management Center for NRG Oncology, a National Cancer Institute sponsored multi-center clinical trials group with over 500 recruitment sites in North America and beyond and over 100 active clinical trials. Dr. Dignam's methodology interests include trial monitoring and early stopping rules, competing risks, hazard function estimation, and prognostic modeling. He also has engaged in and led investigations into sociodemographic factors such as race/ethnicity and BMI/obesity on cancer prognosis and treatment response. Courses taught include introductory biostatistics, clinical trials, survival analysis, and regression modeling methods.
University of Pittsburgh, Graduate School of Public Health
Pittsburgh
PhD - Biostatistics
1994
Saint Xavier College
Chicago
BA - Mathematics
1986
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy.
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
PMID: 35753553
Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup. J Urol. 2022 06; 207(6):1236-1245.
PMID: 35050703
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.
Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2021 06 20; 39(18):2037-2048.
PMID: 33939491
Disparities in Breast Cancer: Narrowing the Gap.
Disparities in Breast Cancer: Narrowing the Gap. J Natl Cancer Inst. 2021 04 06; 113(4):349-350.
PMID: 32986842
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552.
PMID: 33570548
Statistical Considerations in the Evaluation of Continuous Biomarkers.
Statistical Considerations in the Evaluation of Continuous Biomarkers. J Nucl Med. 2021 05 10; 62(5):605-611.
PMID: 33579807
Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology.
Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology. Int J Radiat Oncol Biol Phys. 2020 10 01; 108(2):483-485.
PMID: 32890539
Disparities in Breast Cancer: Narrowing the Gap.
Dignam JJ. Disparities in Breast Cancer: Narrowing the Gap. J Natl Cancer Inst. 2020 Sep 28.
PMID: 32986842
Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures?
Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures? Qual Life Res. 2021 Jan; 30(1):81-89.
PMID: 32894431
Predictors of pressure injury development in critically ill adults: A retrospective cohort study.
Sala JJ, Mayampurath A, Solmos S, Vonderheid SC, Banas M, D'Souza A, LaFond C. Predictors of pressure injury development in critically ill adults: A retrospective cohort study. Intensive Crit Care Nurs. 2021 Feb; 62:102924.
PMID: 11773293
Co-recipient, Statistical Partnership Among Academe, Industry, and Government (SPAIG) Award
American Statistical Association
2021
Elected Fellow
Society for Clinical Trials
2019
Inducted Member
Delta Omega, National Public Health Honor Society
1991